The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas
- 1 December 1987
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 23 (12), 1921-1924
- https://doi.org/10.1016/0277-5379(87)90060-5
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Growth inhibitory effects of 5-aza-2′-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation inductionBiochemical and Biophysical Research Communications, 1986
- Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2′-deoxycytidine and β-2′-deoxythioguanosineInternational Journal of Cancer, 1982
- Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine.Journal of Biological Chemistry, 1982
- Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemiaLeukemia Research, 1981
- Toxicology in Mice of the Antileukemic Agent 5-AZA-2'-DeoxycytidineDrug and Chemical Toxicology, 1981
- Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinaseBiochemical Pharmacology, 1979
- EFFECT OF INTRAVENOUS-INFUSION OF 5-AZA-2'-DEOXYCYTIDINE ON SURVIVAL TIME OF MICE WITH L1210 LEUKEMIA1978
- Correlation between Hypomethylation of DNA and Expression of Globin Genes in Friend Erythroleukemia CellsEuropean Journal of Biochemistry, 1977